Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226999 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
A Phase 2 study of Small Cell Lung Cancer (SCLC), sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 550
- Enrollment target
- 6
- Study locations
NCT07226999: Recruiting Phase 2 study of Small Cell Lung Cancer (SCLC), sponsored by Pfizer.
NCT07226999 is a Phase 2 study of Small Cell Lung Cancer (SCLC) that is actively recruiting participants, run by Pfizer. The registered enrollment target is 550 participants, above the 248-participant average among 12 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (122% higher). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226999, a Phase 2 study of Small Cell Lung Cancer (SCLC), is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 550 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have extensive-stage small cell lung cancer confirmed by lab tests. * Have not received chemotherapy or radiation for this type of lung cancer. * Be in good physical condition and have healthy organs based on medical tests. The study has two parts: * In the first part, researchers will check how safe the study medicine is and how well people tolerate it when given with chemotherapy. * In the second part, they will compare study medicine plus chemotherapy to another approved treatment (atezolizumab plus chemotherapy) to see which works better. Participants will receive the treatment through IV infusions (medicine given directly into a vein). The treatment will be given in repeated time periods called cycles. Some participants will continue receiving the study medicine alone after the initial treatment.
Primary Outcome
Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) is observed as best overall response. ORR using RECIST v1.1 as assessed by investigator.
Conditions Studied
Interventions
- BIOLOGICAL Atezolizumab
- DRUG Chemotherapy
- DRUG PF-08634404
Study Locations (6)
Texas
- Texas Oncology - San Antonio - San Antonio
- Texas Oncology - Gulf Coast - Webster
Arkansas
- Highlands Oncology Group - Springdale
Florida
- Mid Florida Hematology and Oncology Center - Orange City
Osaka
- Kansai Medical University Hospital - Hirakata
Other
- Pan American Center for Oncology Trials, LLC - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2025-12-09 |
| Est. Completion | 2034-03-11 |
| Phase | Phase 2 |
What NCT07226999 shows while recruiting
NCT07226999 is an interventional study that assigns participants to a tested intervention. The registered 550 participants enrollment target is mid-sized for trials with a published cap, above the 248-participant average among 12 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (122% higher).
The record links to 1 condition, with Small Cell Lung Cancer (SCLC) appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT07226999 lists 6 locations in 5 states (Texas, Arkansas, Florida).
Frequently Asked Questions
What is clinical trial NCT07226999 about?
NCT07226999 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer". This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body. To join the study, participants m...
What is the current status of trial NCT07226999?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 550 participants. The study started on 2025-12-09. Estimated completion is 2034-03-11.
What conditions does trial NCT07226999 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer (SCLC).
What interventions are being tested in trial NCT07226999?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), Chemotherapy (DRUG), PF-08634404 (DRUG).
Who is sponsoring clinical trial NCT07226999?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226999 being conducted?
This trial has 6 study locations across Arkansas, Florida, Texas, Osaka, Other. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Cancer (SCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07226999's enrollment target sits among peer trials
550 2nd of 12 the highest of 12 other Small Cell Lung Cancer (SCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small Cell Lung Cancer (SCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
RECRUITING · Phase 2
-
SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer
RECRUITING · Phase 2
-
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
ACTIVE NOT RECRUITING · Phase 2
-
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
RECRUITING · Phase 1
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
- NCT03474913 · 550 participants
Upright MRI for Prostate Cancer Screening
- NCT04761120 · 550 participants
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI